

Katia Todoerti

CURRICULUM VITAE

PERSONAL INFORMATION

Address: Viale Monte Nero, 76

20135, Milan, ITALY

Phone: +39 3395621257

E-mail: katiatodoerti@gmail.com

Sex: Female

Date of birth: 27/11/1978

C.F.: TDRKTA78S67B885U

WORK EXPERIENCE

01.01.2018-Present: one-year fellowship by Fondazione Umberto Veronesi (FUV)

Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy

Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy, directed by Prof. Antonino Neri

Project: Functional analysis of long-non coding RNAs deregulated in plasma cells dyscrasias

01.01.2017-31.12.2017: project-contract by Referral Cancer Center of Basilicata, IRCCS-CROB, Rionero in Vulture, (PZ), Italy

Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Dr. Pellegrino Musto

Project: Definition of the epigenetic signature in Multiple Myeloma by high-resolution DNA methylation profiling and integrated analysis with genomic imbalance, gene and microRNA expression

01.01.2013-01.01.2017: Three-years and one-year renewal project-contract, as Principal Investigator by a young researcher grant of the Italian Ministry of Health

Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Rionero in Vulture, (PZ) Italy, Dr. P. Musto

Project: Definition of the epigenetic signature in Multiple Myeloma by high-resolution DNA methylation profiling and integrated analysis with genomic imbalance, gene and microRNA expression

01.11.2010-31.10.2012: Two-years renewal post-doc fellowship by University of Milan

Laboratory of Molecular Genetics, O.U. Haematology 1, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Medical Sciences, University of Milan, Milan, Italy, Professor A. Neri

Project: Study of microRNAs' role in Multiple myeloma, by integrative genomics analysis

01.11.2008-31.10.2010: Two-years post-doc fellowship by University of Milan

Laboratory of Molecular Genetics, O.U. Haematology 1, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Medical Sciences, University of Milan, Milan, Italy, Professor A. Neri

Project: Bone marrow microenvironment and neoplastic clone in Multiple myeloma; identification of pathways and potential molecular targets

01.01.2006-31.12.2008: Three-years fellowship by Italian Foundation for Cancer Research (FIRC)

Laboratory of Molecular Genetics, O.U. Haematology 1, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Medical Sciences, University of Milan, Milan, Italy, Dr. A. Neri

Project: Genome-wide and gene expression profiling analyses in Multiple myeloma

01.01.2005-31.12.2005: One-year fellowship by Ospedale Maggiore Policlinico IRCCS of Milan Laboratory of Molecular Genetics, O.U. Haematology 1, Ospedale Maggiore Policlinico IRCCS, Department of Medical Sciences, University of Milan, Milan, Italy, directed by Dr. A. Neri
Project: Gene expression profiling analysis in Multiple myeloma patients carrying distinct types of IgH chromosomal translocations

01.01.2004-31.12.2004: One-year fellowship by FIRC Laboratory of Molecular Genetics, O.U. Haematology 1, Ospedale Maggiore Policlinico IRCCS, Department of Medical Sciences, University of Milan, Milan, Italy, directed by Dr. A. Neri
Project: Study of functional role of MMSET proteins

EDUCATION AND TRAINING

2006-2008: PhD in Experimental Hematology, University of Milan (Dep. Medical Science), Italy
Thesis title “Integrative Genomics in Molecular Analysis of Multiple Myeloma”

1997-2003: Biotechnology Degree summa cum laude, University of Bologna, Italy
Thesis title “Functional Analysis of the proteins encoded by the gene WHSC1/MMSET, involved in t(4;14) in Multiple Myeloma: recruitment of molecules with histone-deacetylase activity”

1992-1997: High school Diploma (60/60), Leon Battista Alberti High school, Valenza (AL), Italy

Courses:

- *R for biological data. R4BD.* EuroClone Spa, Pero (MI), November 18-19, 2017.
- *European projecting Course.* European Institute for Social-Economic Development (ISES, “Istituto Europeo per lo Sviluppo Socio-Economico”), Alessandria, January 15-16, 2015.
- *Cytoscan join the Resolution Revolution Workshop.* Rome, May 10, 2012.
- *Data EXON 1.0 ST arrays analysis Course.* Orbassano (TO), June 24-26, 2008.
- *Partek training Workshop.* London, May 6-7, 2008.
- *Exon and Partek Workshop.* Milan, December 5, 2007.
- *International Summer School on statistical inference in biology and human sciences, BIOSTAT2006.* University of Piemonte Orientale, Asti, June 27 - July 7, 2006.
- *4th Covention on “real time” PCR. Technological approaches in the post-genomic era.* Milan, September 12, 2006.
- *Promega’s ABC: Principles and Applications of Promega’s Luciferase Reporter Assays.* Milan, July 2004.

PERSONAL SKILLS

Mother Tongue: Italian

Other language(s):

English: Good level

Technical skills and Competences:

Cell Biology: cell culture of adherent and suspension human cell lines; cell transfection; analysis of transcriptional activity; analysis of protein expression (subcellular fractioning, immunofluorescence, western blotting, immunoprecipitation); confocal microscopy; purification of CD138+ plasma cells from bone marrow samples.

Molecular Biology: gene cloning; polymerase chain reaction (PCR) and Real-Time Quantitative PCR; microarray technology (global gene, microRNA and lncRNA expression profiling, genome-wide profiling on Affymetrix platform, global methylation profiling on Illumina platform).

Bioinformatics: knowledge of Windows OS; Microsoft Office (Access, Excel, Powerpoint, Word); graphics tools and image editing; data-mining softwares for microarray analysis; mining of public genomic data; basic use of R and Bioconductor.

RESEARCH EXPERIENCE:

Present: Research activity at the Hematology Unit of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Oncology and Hemato-oncology, University of Milan. Global expression profiling studies on long non-coding RNAs, in PC dyscrasias and other hematological malignances.

2013-2017: Research activity at the Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture. Acquisition of genome-wide methylation profiling methods (Illumina Platform) and application on PC dyscrasia dataset. Application of integrative analyses on multi-platform data.

Other collaborative projects in the molecular characterization of thyroid carcinoma by microarray profiling analyses.

2003-2012: Research activity at the O.U. Haematology 1, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Medical Sciences, University of Milan. Study of the functional role of MMSET gene in Multiple Myeloma (MM). Gene, miRNA and genome-wide profiling studies on highly purified plasma cell (PC) samples from MM and Plasma Cell Leukemia (PCL) patients, aimed at defining transcriptional and molecular features associated with malignant PC evolution and in relation to drug treatment. Application of the same high-throughput technology in several collaborative projects, in the molecular characterization of i) MM bone microenvironment cells such as endothelial, mesenchymal cells and osteoblasts, ii) other different hematological malignancies such as Chronic Lymphocytic Leukemia, iii) the response to drug treatment in human cell lines.

AWARDS

2018: Competitive research fellowship by Fondazione Umberto Veronesi.

2009-2012: Competitive research fellowship by University of Milan.

2006-2008: Competitive research fellowship by FIRC.

2005: Competitive research fellowship by Ospedale Maggiore Policlinico IRCCS of Milan.

2004: Competitive research fellowship by FIRC.

Invited presentations:

- Oral presentation on "*Identification of MRD in Multiple Myeloma: Next Generation Sequencing*", at AMGEN Convention "Personalized medicine in hematology: focus on Multiple myeloma". Naples, October 12, 2017.

- Oral presentation as first author of the publication "*Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome*", at Investigator Research Meeting- Preclinical study and translational research Congress, Naples, September 23, 2014.

- Oral presentation as first author of the publication "*Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome*", at the Final Contest of "Under 40 in Hematology 2013" Project. Turin, November 14-15, 2013.

GRANTS

01.01.2013-01.01.2017: Principal Investigator of Young Researcher Grant of the Italian Ministry of Health (Progetti di Ricerca Giovani Ricercatori – Ricerca Finalizzata 2010)

Institution: IRCCS-CROB, Referral Cancer Center of Basilicata, Laboratory of Pre-Clinical and Translational Research, Rionero in Vulture (PZ), Italy

Project code: GR-2010-2320635

Duration: three years

Total Funding: €371.200

Project title: “*Definition of the epigenetic signature in Multiple Myeloma by high-resolution DNA methylation profiling and integrated analysis with genomic imbalance, gene and microRNA expression*”

Memberships:

- Ordinary member of the “Società Italiana di Ematologia”, SIE.
- Ordinary member of the “Società Italiana di Ematologia Sperimentale”, SIES.

MEETINGS

- *Novel insights in biology myeloma: the seed and soil.* Catania, February 17-18, 2017. Oral presentation.
- *Convention on medical research at IRCCS CROB. Oncology Translational research Workshop.* Rionero in Vulture, December 5-6, 2016.
- *14th SIES National Congress.* Rimini, October 19-21, 2016. Oral presentation.
- *Meeting on General States of Health Research.* Rome, April 27-28, 2016. Poster presentation of young researcher project’ results.
- *Convention on medical research at IRCCS CROB.* Rionero in Vulture, December 17, 2015.
- *45th National Congress of the Italian Society of Hematology (SIE).* Florence, October 4-7, 2015. Oral presentations and posters.
- *Convention on medical research at IRCCS CROB: results in 2014 and perspectives for 2015.* Rionero in Vulture, December 17-18, 2014. Oral presentation of young researcher project’ results.
- *13th National Congress of the Italian Society of Experimental Hematology (SIES).* Rimini, October 15-17, 2014. Oral presentations.
- *Investigator Research Meeting-Preclinical study and Translational research.* Naples, September 23, 2014. Oral presentation.
- *EHA 2014 - 19th European Hematology Association Congress, Hematology Medical Congress.* Milan, June 12-15, 2014. Poster.
- *Convention on translational research and advanced cancer diagnostics at IRCCS-CROB: results in 2013 and perspectives for 2014.* Rionero in Vulture, December 16, 2013. Oral presentation of young researcher project’ results.
- *44th SIE National Congress.* Verona, October 20-23, 2013. Posters.
- *SIES Convention on microRNA.* Florence, November 22, 2012.
- *12th SIES National Congress.* Rome, October 17-19, 2012. Oral presentation.
- *16th EHA Congress.* London, June 9-12, 2011. Oral presentation.
- *Translational medicine in multiple myeloma Workshop.* Milan, October 11, 2010.
- *11th SIES National Congress.* Turin, October 6-8, 2010. Poster.
- *Updates on microRNA Research Workshop (EuroClone).* Milan, July 6, 2010.
- *Convention on the new acquisitions and therapeutic perspectives in multiple myeloma.* Parma, June 12, 2009.
- *14th EHA Congress.* Berlin, June 4-7, 2009. Poster.
- *10th SIES National Congress.* Bari, September 24-26, 2008. Oral presentation.
- *RNAi Workshop (Celbio).* Milan, May 15, 2008.
- *The ESH Euroconference on Multiple Myeloma and other Monoclonal Gammopathies.* Cascais, March 6-9, 2008.

- 49th National Congress of the Italian Society of Cancerology (SIC, "Società Italiana di Cancerologia"). Pordenone, November 26-29, 2007. Poster.
- 4th course on hematological cancers. Milan, November 16, 2007.
- The RNA symposia series: Messenger, Micro and Interfering. Milan, November 15, 2006.
- 40th SIE National Congress. Bergamo, July 3-6, 2005. Poster.
- 13th SIES National Congress. Pavia, September 14-16, 2004. Oral presentation.

PUBLICATIONS

Summary:

Papers: 76, from 2005 to present

H-index: 22 (calculated on 74 cited documents, source: Scopus, January 25, 2018)

Total citations: 1525 (calculated on 74 publications, source: Scopus, January 05, 2018)

1. Cagnetta A, Soncini D, Orecchioni S, Talarico G, Minetto P, Guolo F, Retali V, Colombo N, Carminati E, Clavio M, Miglino M, Bergamaschi M, Nahimana A, Duchosal M, **Todoerti K**, Neri A, Passalacqua M, Bruzzone S, Nencioni A, Bertolini F, Gobbi M, Lemoli RM, Cea M. *Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents*. Haematologica. 2018 **IF 2016: 7.700**
2. Anania MC, Cetti E, Lecis D, **Todoerti K**, Gulino A, Mauro G, Di Marco T, Cleris L, Pagliardini S, Manenti G, Belmonte B, Tripodo C, Neri A, Greco A. *Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells*. Cancer Lett. 2017 **IF 2016: 6.375**
3. La Rocca F, Airoidi I, Di Carlo E, Marotta P, Falco G, Simeon V, Laurenzana I, Trino S, De Luca L, **Todoerti K**, Villani O, Lackmann M, D'Auria F, Frassoni F, Neri A, Del Vecchio L, Musto P, Cilloni D, Caivano A. *EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells*. Cell Oncol (Dordr). 2017 **IF 2016: 3.786**
4. Bolzoni M, Ronchetti D, Storti P, Donofrio G, Marchica V, Costa F, Agnelli L, Toscani D, Vescovini R, **Todoerti K**, Bonomini S, Sammarelli G, Vecchi A, Guasco D, Accardi F, Palma BD, Gamberi B, Ferrari C, Neri A, Aversa F, Giuliani N. *IL21R expressing CD14⁺CD16⁺ monocytes expand in multiple myeloma patients leading to increased osteoclasts*. Haematologica. 2017 **IF 2016: 7.700**
5. Ronchetti D, Manzoni M, **Todoerti K**, Neri A, Agnelli L. *In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma*. Genes (Basel). 2016 **IF 2016: 3.600**
6. Neri A, **Todoerti K**, Lionetti M, Simeon V, Barbieri M, Nozza F, Vona G, Pompa A, Baldini L, Musto P. *Primary plasma cell leukemia 2.0: advances in biology and clinical management*. Expert Rev Hematol. 2016. Review. **IF 2016: 1.420**
7. Marchica V, Accardi F, Storti P, Mancini C, Martella E, Dalla Palma B, Bolzoni M, **Todoerti K**, Marcatti M, Schifano C, Bonomini S, Sammarelli G, Neri A, Ponzoni M, Aversa F, Giuliani N. *Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?* Int J Hematol. 2017 **IF 2016: 1.610**
8. Salazar G, Bellocchi C, **Todoerti K**, Saporiti F, Piacentini L, Scorza R, Colombo GI. *Time-course gene expression data on the transcriptional effects of Aminaphtone on ECV304 endothelial cells*. Data Brief. 2016
9. Colombo M, Galletti S, Bulfamante G, Falleni M, Tosi D, **Todoerti K**, Lazzari E, Crews LA, Jamieson CH, Ravaioli S, Baccianti F, Garavelli S, Platonova N, Neri A, Chiaramonte R. *Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche*. Oncotarget. 2016 **IF 2016: 5.008**
10. Storti P, Marchica V, Airoidi I, Donofrio G, Fiorini E, Ferri V, Guasco D, **Todoerti K**, Silbermann R, Anderson JL, Zhao W, Agnelli L, Bolzoni M, Martella E, Mancini C, Campanini N, Noonan DM, Petronini

- PG, Neri A, Aversa F, Roodman GD, Giuliani N. *Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo*. *Leukemia*. 2016 **IF 2016: 11.702**
11. Bolzoni M, Chiu M, Accardi F, Vescovini R, Airolidi I, Storti P, **Todoerti K**, Agnelli L, Missale G, Andreoli R, Bianchi MG, Allegri M, Barilli A, Nicolini F, Cavalli A, Costa F, Marchica V, Toscani D, Mancini C, Martella E, Dall'Asta V, Donofrio G, Aversa F, Bussolati O, Giuliani N. *Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target*. *Blood*. 2016 **IF 2016: 13.164**
 12. Salazar G, Bellocchi C, **Todoerti K**, Saporiti F, Piacentini L, Scorza R, Colombo GI. *Gene expression profiling reveals novel protective effects of Aminaphtone on ECV304 endothelial cells*. *Eur J Pharmacol*. 2016. **IF 2016: 2.896**
 13. Musto P, Simeon V, **Todoerti K**, Neri A. *Primary Plasma Cell Leukemia: Identity Card 2016*. *Curr Treat Options Oncol*. 2016. Review. **IF 2016: 2.820**
 14. Ronchetti D, Agnelli L, Taiana E, Galletti S, Manzoni M, **Todoerti K**, Musto P, Strozzi F, Neri A. *Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma*. *Oncotarget*. 2016 **IF 2016: 5.008**
 15. Minna E, Romeo P, Dugo M, De Cecco L, **Todoerti K**, Pilotti S, Perrone F, Seregini E, Agnelli L, Neri A, Greco A, Borrello MG. *miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma*. *Oncotarget*. 2016 **IF 2016: 5.008**
 16. Lionetti M, Barbieri M, Manzoni M, Fabris S, Bandini C, **Todoerti K**, Nozza F, Rossi D, Musto P, Baldini L, Neri A. *Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature*. *Oncotarget*. 2016 **IF 2016: 5.008**
 17. Gentile M, Shanafelt TD, Cutrona G, Molica S, Tripepi G, Alvarez I, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, **Todoerti K**, Matis S, Musolino C, Fabris S, Vigna E, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Arcari A, Federico M, Mannina D, Recchia AG, Neri A, Kay NE, Ferrarini M, Morabito F. *A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients*. *Leukemia*. 2015 **IF 2016: 11.702**
 18. Calura E, Bisognin A, Manzoni M, **Todoerti K**, Taiana E, Sales G, Morgan GJ, Tonon G, Amodio N, Tassone P, Neri A, Agnelli L, Romualdi C, Bortoluzzi S. *Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients*. *Oncotarget*. 2015 **IF 2016: 5.008**
 19. Barbieri M, Manzoni M, Fabris S, Ciceri G, **Todoerti K**, Simeon V, Musto P, Cortelezzi A, Baldini L, Neri A, Lionetti M. *Compendium of FAM46C gene mutations in plasma cell dyscrasias*. *Br J Haematol*. 2015 **IF 2016: 5.670**
 20. Anania M, Gasparri F, Cetti E, Fraietta I, **Todoerti K**, Miranda C, Mazzoni M, Re C, Colombo R, Ukmar G, Camisasca S, Pagliardini S, Pierotti M, Neri A, Galvani A, Greco A. *Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening*. *Oncotarget*. 2015 **IF 2016: 5.008**
 21. Lionetti M, Barbieri M, **Todoerti K**, Agnelli L, Fabris S, Tonon G, Segalla S, Cifola I, Pinatel E, Tassone P, Musto P, Baldini L, Neri A. *A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias*. *Oncotarget*. 2015 **IF 2016: 5.008**
 22. Simeon V, **Todoerti K**, La Rocca F, Caivano A, Trino S, Lionetti M, Agnelli L, De Luca L, Laurenzana I, Neri A, Musto P. *Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine*. *Int J Mol Sci*. 2015. Review. **IF 2016: 3.226**
 23. Chiamonte R, Colombo M, Bulfamante G, Falleni M, Tosi D, Garavelli S, De Simone D, Vigolo E, **Todoerti K**, Neri A, Platonova N. *Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1 α chemokine system*. *Int J Biochem Cell Biol*. 2015. **IF 2016: 3.505**
 24. Lionetti M, Barbieri M, **Todoerti K**, Agnelli L, Marzorati S, Fabris S, Ciceri G, Galletti S, Milesi G, Manzoni M, Mazzoni M, Greco A, Tonon G, Musto P, Baldini L, Neri A. *Molecular spectrum of BRAF*,

NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget. 2015 **IF 2016: 5.008**

25. Cifola I, Lionetti M, Pinatel E, **Todoerti K**, Mangano E, Pietrelli A, Fabris S, Mosca L, Simeon V, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Caravita T, Battaglia C, De Bellis G, Palumbo A, Musto P, Neri A. *Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.* Oncotarget. 2015 **IF 2016: 5.008**
26. Segalla S, Pivetti S, **Todoerti K**, Chudzik MA, Giuliani EC, Lazzaro F, Volta V, Lazarevic D, Musco G, Muzi-Falconi M, Neri A, Biffo S, Tonon G. *The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA.* Nucleic Acids Res. 2015 **IF 2016: 10.162**
27. Gentile M, Cutrona G, Molica S, Ilariucci F, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, **Todoerti K**, Matis S, Musolino C, Fabris S, Lionetti M, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Musto P, Federico M, Neri A, Ferrarini M, Morabito F. *Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukaemia patients: results of the multicenter o-cll1-gisl study.* Eur J Haematol. 2015 **IF 2016: 2.653**
28. Colombo M, Thümmel K, Mirandola L, Garavelli S, **Todoerti K**, Apicella L, Lazzari E, Lancellotti M, Platonova N, Akbar M, Chiriva-Internati M, Soutar R, Neri A, Goodyear CS, Chiaramonte R. *Notch signaling drives multiple myeloma induced osteoclastogenesis.* Oncotarget. 2014 **IF 2016: 5.008**
29. Morabito F, Cutrona G, Gentile M, Fabris S, Matis S, Vigna E, **Todoerti K**, Colombo M, Recchia AG, Bossio S, De Stefano L, Ilariucci F, Cortelezzi A, Consoli U, Vincelli I, Pesce EA, Musolino C, Molica S, Di Raimondo F, Neri A, Ferrarini M. *Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study.* Br J Haematol. 2015. **IF 2016: 5.670**
30. Verdelli D, Nobili L, **Todoerti K**, Mosca L, Fabris S, D'Anca M, Pellegrino E, Piva R, Inghirami G, Capelli C, Introna M, Baldini L, Chiaramonte R, Lombardi L, Neri A. *Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.* Genes Chromosomes Cancer. 2014. **IF 2016: 3.696**
31. Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantonio G, Villani O, Bringhen S, Omedè P, Lerosé R, Agnelli L, **Todoerti K**, Neri A, Boccadoro M, Palumbo A. *Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.* Leukemia. 2014 **IF 2016: 11.702**
32. Wu P, Agnelli L, Walker BA, **Todoerti K**, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ. *Improved risk stratification in myeloma using a microRNA-based classifier.* Br J Haematol. 2013 **IF 2016: 5.670**
33. Scavullo C, Servida F, Lecis D, Onida F, Drago C, Ferrante L, Seneci P, Barcellini W, Lionetti M, **Todoerti K**, Neri A, Delia D, Deliliers GL. *Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL).* Leuk Res. 2013 **IF 2016: 2.501**
34. Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, **Todoerti K**, Tuana G, Mosca L, Gallo Cantafio ME, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omedè P, Morabito F, Tassone P, Boccadoro M, Palumbo A, Neri A. *Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia.* Clin Cancer Res. 2013 **IF 2016: 9.619**
35. **Todoerti K**, Agnelli L, Fabris S, Lionetti M, Tuana G, Mosca L, Lombardi L, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Omedè P, Tassone P, Boccadoro M, Palumbo A, Neri A, Musto P. *Transcriptional*

Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome. Clin Cancer Res. 2013 **IF 2016: 9.619**

36. Ronchetti D, **Todoerti K**, Tuana G, Agnelli L, Mosca L, Lionetti M, Fabris S, Colapietro P, Miozzo M, Ferrarini M, Tassone P, Neri A. *The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma.* Blood Cancer J. 2012 **IF 2016: 4.411**
37. Bolzoni M, Storti P, Bonomini S, **Todoerti K**, Guasco D, Toscani D, Agnelli L, Neri A, Rizzoli V, Giuliani N. *Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.* Exp Hematol. 2013 **IF 2016: 2.820**
38. Mosca L., Musto P., **Todoerti K.**, Barbieri M., Agnelli L., Fabris S., Tuana G., Lionetti M., Bonaparte E., Sirchia M.S., Grieco V., Bianchino G, D'Auria F., Statuto T., Mazzoccoli C., De Luca L., Petrucci M:T., Morabito F., Offidani M., Di Raimondo F., Falcone A., Caravita T., Omede' P., Boccadoro M., Palumbo A., Neri A. *Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles.* Am J Hematol. 2013 **IF 2016: 5.275**
39. Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, **Todoerti K**, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC. *Canonical and non canonical Hedgehog pathway in the pathogenesis of multiple myeloma.* Blood 2012. **IF 2016: 13.164**
40. Calzada AA, **Todoerti K**, Donadoni L, Pelliccioli A, Tuana G, Gatta R, Neri A, Finazzi G, Mantovani R, Rambaldi A, Introna M, Lombardi L, Golay J. *The HDAC Inhibitor Givinostat Modulates the Hematopoietic Transcription Factors NFE2 and C-MYB in JAK2V617F Myeloproliferative Neoplasm Cells.* Exp Hematol. 2012. **IF 2016: 2.820**
41. Agnelli L, Storti P, **Todoerti K**, Sammarelli G, Dalla Palma B, Bolzoni M, Rocci A, Piazza F, Semenzato G, Palumbo A, Neri A, Giuliani N. *Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations.* Am J Hematol. 2011 **IF 2016: 5.275**
42. Biasiolo M, Sales G, Lionetti M, Agnelli L, **Todoerti K**, Bisognin A, Coppe A, Romualdi C, Neri A, Bortoluzzi S. *Impact of host genes and strand selection on miRNA and miRNA* expression.* PLoS One. 2011. **IF 2016: 3.540**
43. Agnelli L, Forcato M, Ferrari F, Tuana G, **Todoerti K**, Walker BA, Morgan GJ, Lombardi L, Biccato S, Neri A. *The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma.* Clin Cancer Res. 2011 **IF 2016: 9.619**
44. Fracchiolla NS, **Todoerti K**, Bertazzi PA, Servida F, Corradini P, Carniti C, Colombi A, Pesatori A, Neri A, Deliliers GL. *Dioxin exposure of human CD34(+) hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects.* Toxicology. 2011. **IF 2016: 3.582**
45. Storti P, Donofrio G, Colla S, Airolidi I, Bolzoni M, Agnelli L, Abeltino M, **Todoerti K**, Lazzaretti M, Mancini C, Ribatti D, Bonomini S, Franceschi V, Pistoia V, Lisignoli G, Pedrazzini A, Cavicchi O, Neri A, Rizzoli V, Giuliani N. *HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.* Leukemia. 2010. **IF 2016: 11.702**
46. Abeltino M, Bonomini S, Bolzoni M, Storti P, Colla S, **Todoerti K**, Agnelli L, Neri A, Rizzoli V, Giuliani N. *The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.* Exp Hematol. 2011. **IF 2016: 2.820**
47. Mosca L, Fabris S, Lionetti M, **Todoerti K**, Agnelli L, Morabito F, Cutrona G, Andronache A, Matis S, Ferrari F, Gentile M, Spriano M, Callea V, Festini G, Molica S, Deliliers GL, Biccato S, Ferrarini M, Neri

A. *Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion.* Clin Cancer Res. 2010. **IF 2016: 9.619**

48. Colla S, Storti P, Donofrio G, **Todoerti K**, Bolzoni M, Lazzaretti M, Abeltino M, Ippolito L, Neri A, Ribatti D, Rizzoli V, Martella E, Giuliani N. *Low bone marrow oxygen tension and hypoxia-inducible factor-1 α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells.* Leukemia. 2010. **IF 2016: 11.702**
49. Giuliani N, Lisignoli G, Novara F, Storti P, Zaffaroni N, Villa R, Sammarelli G, Agnelli L, **Todoerti K**, Bernardo ME, Manferdini C, Colla S, Abeltino M, Bolzoni M, Rocci A, Gabusi E, Palumbo A, Zuffardi O, Neri A, Rizzoli V. *Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients.* Leukemia. 2010. **IF 2016: 11.702**
50. Cro L, Ferrario A, Lionetti M, Bertoni F, Zucal N, Nobili L, Fabris S, **Todoerti K**, Cortelezzi A, Guffanti A, Goldaniga M, Marcheselli L, Neri A, Lambertenghi-Delilieri G, Baldini L. *The clinical and biological features of a series of immunophenotypic variant of B-CLL.* Eur J Haematol. 2010. **IF 2016: 2.653**
51. Civallero M, Cosenza M, Grisendi G, Marcheselli L, **Todoerti K**, Sacchi S. *Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines.* Leuk Lymphoma. 2010. **IF 2016: 0.850**
52. Piva R, Agnelli L, Pellegrino E, **Todoerti K**, Grosso V, Tamagno I, Fornari A, Martinoglio B, Medico E, Zamò A, Facchetti F, Ponzoni M, Geissinger E, Rosenwald A, Müller-Hermelink HK, De Wolf-Peeters C, Piccaluga PP, Pileri S, Neri A, Inghirami G. *Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms.* J Clin Oncol. 2010. **IF 2016: 24.008**
53. **Todoerti K**, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C, Codeluppi K, Colla S, Crugnola M, Abeltino M, Bolzoni M, Sgobba V, Facchini A, Lambertenghi-Delilieri G, Zuffardi O, Rizzoli V, Neri A, Giuliani N. *Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.* Exp Hematol. 2010. **IF 2016: 2.820**
54. Molica S, Digiesi G, Vacca A, Mirabelli R, **Todoerti K**, Battaglia C, Morabito F, Neri A, Ribatti D. *Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia?* Adv Hematol. 2009. **IF 2016: 1.600**
55. Biasiolo M, Forcato M, Possamai L, Ferrari F, Agnelli L, Lionetti M, **Todoerti K**, Neri A, Marchiori M, Bortoluzzi S, Bicciato S. *Critical analysis of transcriptional and post-transcriptional regulatory networks in multiple myeloma.* Pac Symp Biocomput. 2010. **IF 2016: 2.750**
56. Lionetti M, Biasiolo M, Agnelli L, **Todoerti K**, Mosca L, Fabris S, Sales G, Delilieri GL, Bicciato S, Lombardi L, Bortoluzzi S, Neri A. *Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma.* Blood. 2009. **IF 2016: 13.164**
57. **Todoerti K**, Barbui V, Pedrini O, Lionetti M, Fossati G, Mascagni P, Rambaldi A, Neri A, Introna M, Lombardi L, Golay J. *Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b.* Haematologica. 2010. **IF 2016: 7.700**
58. Ria R, **Todoerti K**, Berardi S, Coluccia AM, De Luisi A, Mattioli M, Ronchetti D, Morabito F, Guarini A, Petrucci MT, Dammacco F, Ribatti D, Neri A, Vacca A. *Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.* Clin Cancer Res. 2009. **IF 2016: 9.619**
59. Morabito F, Cutrona G, Gentile M, Matis S, **Todoerti K**, Colombo M, Sonaglio C, Fabris S, Reverberi D, Megna M, Spriano M, Lucia E, Rossi E, Callea V, Mazzone C, Festini G, Zupo S, Molica S, Neri A, Ferrarini M. *Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia.* Br J Haematol. 2009. **IF 2016: 5.670**

60. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, **Todoerti K**, Verdelli D, Battaglia C, Bertoni F, Deliliers GL, Neri A. *A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect*. *Genes Chromosomes Cancer*. 2009. **IF 2016: 3.696**
61. Lisignoli G, Codeluppi K, **Todoerti K**, Manferdini C, Piacentini A, Zini N, Grassi F, Cattini L, Piva R, Rizzoli V, Facchini A, Giuliani N, Neri A. *Gene array profile identifies collagen type XV as a novel human osteoblast-secreted matrix protein*. *J Cell Physiol*. 2009. **IF 2016: 4.080**
62. Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, **Todoerti K**, Ronchetti D, Deliliers GL, Neri A. *Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles*. *Genes Chromosomes Cancer*. 2009. **IF 2016: 3.696**
63. Ricci C, Onida F, Servida F, Radaelli F, Saporiti G, **Todoerti K**, Deliliers GL, Ghidoni R. *In vitro anti-leukaemia activity of sphingosine kinase inhibitor*. *Br J Haematol*. 2009. **IF 2016: 5.670**
64. Molica S, Vitelli G, Cutrona G, **Todoerti K**, Mirabelli R, Digiesi G, Giannarelli D, Sperduti I, Molica M, Gentile M, Morabito F, Neri A, Ferrarini M. *Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia*. *Int J Hematol*. 2008. **IF 2016: 1.610**
65. Verdelli D, Nobili L, **Todoerti K**, Intini D, Cosenza M, Civallero M, Bertacchini J, Deliliers GL, Sacchi S, Lombardi L, Neri A. *Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression*. *Hematol Oncol*. 2009. **IF 2016: 3.118**
66. Fabris S, Mosca L, **Todoerti K**, Cutrona G, Lionetti M, Intini D, Matis S, Colombo M, Agnelli L, Gentile M, Spriano M, Callea V, Festini G, Molica S, Lambertenghi Deliliers G, Morabito F, Ferrarini M, Neri A. *Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia*. *Genes Chromosomes Cancer*. 2008. **IF 2016: 3.696**
67. Molica S, Vitelli G, Cutrona G, **Todoerti K**, Mirabelli R, Digiesi G, Morabito F, Neri A, Ferrarini M. *Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia*. *Leuk Lymphoma*. 2008. **IF 2016: 0.850**
68. Fabris S, **Todoerti K**, Mosca L, Agnelli L, Intini D, Lionetti M, Gueneri S, Lambertenghi-Deliliers G, Bertoni F, Neri A. *Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma*. *Genes Chromosomes Cancer*. 2007. **IF 2016: 3.696**
69. Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F, Verdelli D, **Todoerti K**, Lambertenghi-Deliliers G, Lombardi L, Neri A. *Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma*. *Br J Haematol*. 2007. **IF 2016: 5.670**
70. Fabris S, Ronchetti D, Agnelli L, Baldini L, Morabito F, Bicciato S, Basso D, **Todoerti K**, Lombardi L, Lambertenghi-Deliliers G, Neri A. *Transcriptional features of multiple myeloma patients with chromosome 1q gain*. *Leukemia*. 2007. **IF 2016: 11.702**
71. Verdelli D, Mattioli M, Fabris S, Nobili L, Intini D, Gueneri S, **Todoerti K**, Zanella A, Deliliers GL, Lombardi L, Neri A. *Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines*. *Haematologica*. 2005. **IF 2016: 7.700**
72. **Todoerti K**, Ronchetti D, Agnelli L, Castellani S, Marelli S, Deliliers GL, Zanella A, Lombardi L, Neri A. *Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma*. *Br J Haematol*. 2005. **IF 2016: 5.670**

List of four additional papers, as part of the European T-Cell Lymphoma Study Group:

- Scarfò I, Pellegrino E, Mereu E, Kwee I, Agnelli L, Bergaggio E, Garaffo G, Vitale N, Caputo M, Machiorlatti R, Circosta P, Abate F, Barreca A, Novero D, Mathew S, Rinaldi A, Tiacchi E, Serra S, Deaglio S, Neri A, Falini B, Rabadan R, Bertoni F, Inghirami G, Piva R; European T-Cell Lymphoma Study Group. *Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts*. Blood. 2016

IF 2016: 13.164

- Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E, Ponzoni M, Zamò A, Iqbal J, Piccaluga PP, Neri A, Chan WC, Pileri S, Bertoni F, Inghirami G, Piva R; European T-Cell Lymphoma Study Group. *Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma*. Blood. 2012 **IF 2016: 13.164**

-Inghirami G, Pileri SA; **European T-Cell Lymphoma Study Group**. *Anaplastic large-cell lymphoma*. Semin Diagn Pathol. 2011 Review. **IF 2016: 1.895**

-Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, Kwee I, Bertoni F, Piccaluga PP, Pileri SA, Inghirami G; **European T-Cell Lymphoma Study Group**. *Anaplastic lymphoma kinase in human cancer*. J Mol Endocrinol. 2011. Review. **IF 2016: 3.577**

Disclaimers

Il sottoscritto, consapevole delle sanzioni penali nel caso di dichiarazioni non veritiere e falsità negli atti richiamate dall'art. 76 del D.P.R. 445/2000 e dalle leggi speciali in materia, dichiara la veridicità e la completezza di tutte le informazioni contenute nel Curriculum Vitae. Il sottoscritto esprime altresì il proprio consenso affinché i dati personali forniti possano essere trattati nel rispetto del Decreto legislativo 30.6.2003, n. 196.

Milano, 25.01. 2018